Newly introduced repurposing topical ozenoxacin against grade-II acne vulgaris: a case series

To assess the efficacy and safety of a newer fluorine-free quinoline class topical antibiotic, ozenoxacin (1%), as a topical monotherapy in grade-II acne vulgaris (AV). Five female patients between the age group of 18–25 years with grade-II AV were prescribed twice daily topical ozenoxacin (1%) in cream formulation as a monotherapy. The efficacy was analyzed using the visual analog scale and investigator global assessment scoring system. At 4 weeks of treatment follow-up, we observed that the pretreatment and posttreatment visual analog scale and investigator global assessment scores showed remarkable differences with excellent response in all five patients without any adverse effects. The above case series concluded that 1% ozenoxacin could be used as an alternative, potential, and safer topical treatment modality in grade-II AV patients.